Cholinergic modulation of auditory processing, sensory gating and novelty detection in human participants

Psychopharmacology

Volumn 225, Issue 4, 2013, Pages 903-921

  Klinkenberg, Inge ^a   Blokland, Arjan ^a   Riedel, Wim J ^a   Sambeth, Anke ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Acetylcholine; Attention; Cognition; Event related potentials; Mismatch negativity; Muscarinic M1; Schizophrenia; Sensory gating

Indexed keywords

BIPERIDEN; PLACEBO; RIVASTIGMINE;

ADULT; AMPLITUDE MODULATION; ARTICLE; AUDITORY PROCESSING; AUDITORY STIMULATION; BRAIN FUNCTION; CHOLINERGIC SYSTEM; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG WITHDRAWAL; EVOKED AUDITORY RESPONSE; FEMALE; HUMAN; HUMAN EXPERIMENT; LATENT PERIOD; MALE; MISMATCH NEGATIVITY; NEUROMODULATION; NORMAL HUMAN; NOVELTY DETECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY GATING; UNSPECIFIED SIDE EFFECT;

ACOUSTIC STIMULATION; ADOLESCENT; ADULT; AUDITORY PERCEPTION; BIPERIDEN; CHOLINERGIC AGENTS; CHOLINESTERASE INHIBITORS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, AUDITORY; FEMALE; HUMANS; MALE; MUSCARINIC ANTAGONISTS; PHENYLCARBAMATES; SENSORY GATING; YOUNG ADULT;

EID: 84873742732     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-012-2872-0     Document Type: Article

References (118)

1. Adler LE, Pachtman E, Franks RD, Pecevich M, Waldo MC, Freedman R (1982) Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol Psychiatry 17:639-654
2. Adler LE, Olincy A, Waldo M, Harris JG, Griffith J, Stevens K, Flach K, Nagamoto H, Bickford P, Leonard S, Freedman R (1998) Schizophrenia, sensory gating, and nicotinic receptors. Schizophrenia Bull 24:189-202
3. Ally BA, Jones GE, Cole JA, Budson AE (2006) Sensory gating in patients with Alzheimer's disease and their biological children. Am J Alzheimers Dis Other Demen 21:439-447
4. Amenedo E, Diaz F (1998) Aging-related changes in processing of non-target and target stimuli during an auditory oddball task. Biol Psychol 48:235-267
5. Anderer P, Semlitsch HV, Saletu B (1996) Multichannel auditory event-related brain potentials: effects of normal aging on the scalp distribution of N1, P2, N2 and P300 latencies and amplitudes. Electroencephalogr Clin Neurophysiol 99:458-472
6. Anderer P, Saletu B, Semlitsch HV, Pascual-Marqui RD (2003) Non-invasive localization of P300 sources in normal aging and age-associated memory impairment. Neurobiol Aging 24:463-479
7. Baldeweg T, Klugman A, Gruzelier J, Hirsch SR (2004) Mismatch negativity potentials and cognitive impairment in schizophrenia. Schizophr Res 69:203-217
8. Bolden C, Cusack B, Richelson E (1992) Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther 260:576-580
9. Bond A, Lader M (1974) The use of analogue scales in rating subjective feelings. Brit J Med Psychol 80:1-46
10. Bora E, Veznedaroglu B, Kayahan B (2005) The effect of galantamine added to clozapine on cognition of five patients with schizophrenia. Clin Neuropharmacol 28:139-141
11. Boutros N, Torello MW, Burns EM, Wu SS, Nasrallah HA (1995) Evoked potentials in subjects at risk for Alzheimer's disease. Psychiatry Res 57:57-63
12. Boutros NN, Korzyukov O, Jansen B, Feingold A, Bell M (2004) Sensory gating deficits during the mid-latency phase of information processing in medicated schizophrenia patients. Psychiatry Res 126:203-215
13. Boutros NN, Brockhaus-Dumke A, Gjini K, Vedeniapin A, Elfakhani M, Burroughs S, Keshavan M (2009) Sensory-gating deficit of the N100 mid-latency auditory evoked potential in medicated schizophrenia patients. Schizophr Res 113:339-346
14. Bramon E, Croft RJ, McDonald C, Virdi GK, Gruzelier JG, Baldeweg T, Sham PC, Frangou S, Murray RM (2004a) Mismatch negativity in schizophrenia: a family study. Schizophr Res 67:1-10
15. Bramon E, Rabe-Hesketh S, Sham P, Murray RM, Frangou S (2004b) Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophr Res 70:315-329
16. Brockhaus-Dumke A, Schultze-Lutter F, Mueller R, Tendolkar I, Bechdolf A, Pukrop R, Klosterkoetter J, Ruhrmann S (2008) Sensory gating in schizophrenia: P50 and N100 gating in antipsychotic-free subjects at risk, first-episode, and chronic patients. Biol Psychiatry 64:376-384
17. Buchanan RW, Summerfelt A, Tek C, Gold J (2002) An open-label trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr Res 59:29-33
18. Buchanan RW, Conley RR, Dickinson D, Ball MP, Feldman S, Gold JM, McMahon RP (2008) Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry 165:82-89
19. Buchwald JS, Rubinstein EH, Schwafel J, Strandburg RJ (1991) Midlatency auditory evoked responses: differential effects of a cholinergic agonist and antagonist. Electroencephalogr Clin Neurophysiol 80:303-309
20. Cancelli I, Cadore IP, Merlino G, Valentinis L, Moratti U, Bergonzi P, Gigli GL, Valente M (2006) Sensory gating deficit assessed by P50/Pb middle latency event related potential in Alzheimer's disease. J Clin Neurophysiol 23:421-425
21. Clementz BA, Blumenfeld LD (2001) Multichannel electroencephalographic assessment of auditory evoked response suppression in schizophrenia. Exp Brain Res 139:377-390
22. Comerchero MD, Polich J (1999) P3a and P3b from typical auditory and visual stimuli. Clin Neurophysiol 110:24-30
23. Curran HV, Pooviboonsuk P, Dalton JA, Lader MH (1998) Differentiating the effects of centrally acting drugs on arousal and memory: an event-related potential study of scopolamine, lorazepam and diphenhydramine. Psychopharmacology 135:27-36
24. Donchin E (1981) Surprise!.Surprise? Psychophysiology 18:493-513
25. Dyer MA, Freudenreich O, Culhane MA, Pachas GN, Deckersbach T, Murphy E, Goff DC, Evins AE (2008) High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. Schizophr Res 102:88-95
26. Erwin RJ, Turetsky BI, Moberg P, Gur RC, Gur RE (1998) P50 abnormalities in schizophrenia: relationship to clinical and neuropsychological indices of attention. Schizophr Res 33:157-167
27. Farlow MR (2003) Update on rivastigmine. Neurologist 9:230-234
28. Fein G, Biggins C, Van Dyke C (1994) The auditory P50 response is normal in Alzheimer's disease when measured via a paired click paradigm. Electroencephalogr Clin Neurophysiol 92:536-545
29. Fjell AM, Walhovd KB (2004) Life-span changes in P3a. Psychophysiology 41:575-583
30. Fjell AM, Walhovd KB, Fischl B, Reinvang I (2007) Cognitive function, P3a/P3b brain potentials, and cortical thickness in aging. Hum Brain Mapp 28:1098-1116
31. Ford JM (1999) Schizophrenia: the broken P300 and beyond. Psychophysiology 36:667-682
32. Ford JM, Pfefferbaum A (1991) Event-related potentials and eyeblink responses in automatic and controlled processing: effects of age. Electroencephalogr Clin Neurophysiol 78:361-377
33. Friedman JI (2004) Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology 174:45-53
34. Friedman JI, Adler DN, Howanitz E, Harvey PD, Brenner G, Temporini H, White L, Parrella M, Davis KL (2002) A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry 51:349-357
35. Furey ML, Drevets WC (2006) Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry 63:1121-1129
36. Furey ML, Khanna A, Hoffman EM, Drevets WC (2010) Scopolamine produces larger antidepressant and antianxiety effects in women than in men. Neuropsychopharmacol 35:2479-2488
37. Garrido MI, Kilner JM, Stephan KE, Friston KJ (2009) The mismatch negativity: a review of underlying mechanisms. Clin Neurophysiol 120:453-463
38. Gjini K, Arfken C, Boutros NN (2010) Relationships between sensory "gating out" and sensory "gating in" of auditory evoked potentials in schizophrenia: a pilot study. Schizophr Res 121:139-145
39. Gmehlin D, Kreisel SH, Bachmann S, Weisbrod M, Thomas C (2011) Age effects on preattentive and early attentive auditory processing of redundant stimuli: is sensory gating affected by physiological aging? J Gerontol A Biol Sci Med Sci 66:1043-1053
40. Golob EJ, Johnson JK, Starr A (2001a) Auditory event-related potentials during target detection are abnormal in mild cognitive impairment. Clin Neurophysiol 113:151-161
41. Golob EJ, Miranda GG, Johnson JK, Starr A (2001b) Sensory cortical interactions in aging, mild cognitive impairment, and Alzheimer's disease. Neurobiol Aging 22:755-763
42. Golob EJ, Irimajiri R, Starr A (2007) Auditory cortical activity in amnestic mild cognitive impairment: relationship to subtype and conversion to dementia. Brain 130:740-752
43. Grillon C, Courchesne E, Ameli R, Geyer MA, Braff DL (1990) Increased distractibility in schizophrenic patients. Electrophysiologic and behavioral evidence. Arch Gen Psychiatry 47:171-179
44. Grunwald T, Boutros NN, Pezer N, von Oertzen J, Fernandez G, Schaller C, Elger CE (2003) Neuronal substrates of sensory gating within the human brain. Biol Psychiatry 53:511-519
45. Hall MH, Schulze K, Bramon E, Murray RM, Sham P, Rijsdijk F (2006) Genetic overlap between P300, P50, and duration mismatch negativity. Am J Med Genet B Neuropsychiatr Genet 141B:336-343
46. Hämäläinen M, Hari R, Ilmoniemi RJ, Knuutila J, Lounasmaa OV (1993) Magnetoencephalography - theory, instrumentation, and applications to noninvasive studies of the working human brain. Rev Mod Phys 65:413-497
47. Hollmann M, Brode E, Greger G, Müller-Peltzer H, Wetzelsberger N (1984) Biperiden effects and plasma levels in volunteers. Eur J Clin Pharmacol 27:619-621
48. Hollmann M, Müller-Peltzer H, Greger G, Brode E, Perucca E, Grimaldi R, Crema A (1987) Pharmacokinetic-dynamic study on different oral biperiden formulations in volunteers. Pharmacopsychiatry 20:72-77
49. Hong X, Chan RC, Zhuang X, Jiang T, Wan X, Wang J, Xiao B, Zhou H, Jiang L, Weng B (2009) Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia. Schizophr Res 108:151-157
50. Inami R, Kirino E, Inoue R, Arai H (2005) Transdermal nicotine administration enhances automatic auditory processing reflected by mismatch negativity. Pharmacol Biochem Behav 80:453-461
51. Iragui VJ, Kutas M, Mitchiner MR, Hillyard SA (1993) Effects of aging on event-related brain potentials and reaction times in an auditory oddball task. Psychophysiology 30:10-22
52. Irimajiri R, Golob EJ, Starr A (2005) Auditory brain-stem, middle- and long-latency evoked potentials in mild cognitive impairment. Clin Neurophysiol 116:1918-1929
53. Jann MW, Shirley KL, Small GW (2002) Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 41:719-739
54. Jasper H (1958) The ten-twenty electrode system of the international federation. Electroencephalogr Clin Neurophysiol 10:371-375
55. Javitt DC, Spencer KM, Thaker GK, Winterer G, Hajós M (2008) Neurophysiological biomarkers for drug development in schizophrenia. Nat Rev Drug Discov 7:68-83
56. Jeon YW, Polich J (2001) P300 asymmetry in schizophrenia: a meta-analysis. Psychiatry Res 104:61-74
57. Jin Y, Potkin SG, Patterson JV, Sandman CA, Hetrick WP, Bunney WE Jr (1997) Effects of P50 temporal variability on sensory gating in schizophrenia. Psychiatry Res 70:71-81
58. Jin Y, Bunney WE Jr, Sandman CA, Patterson JV, Fleming K, Moenter JR, Kalali AH, Hetrick WP, Potkin SG (1998) Is P50 suppression a measure of sensory gating in schizophrenia? Biol Psychiatry 43:873-878
59. Johannesen JK, Kieffaber PD, O'Donnell BF, Shekhar A, Evans JD, Hetrick WP (2005) Contributions of subtype and spectral frequency analyses to the study of P50 ERP amplitude and suppression in schizophrenia. Schizophr Res 78:269-284
60. Johnstone EC, Crow TJ, Ferrier IN, Frith CD, Owens DGC, Bourne RC, Gamble SJ (1983) Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychol Med 13:513-527
61. Juckel G, Clotz F, Frodl T, Kawohl W, Hampel H, Pogarell O, Hegerl U (2008) Diagnostic usefulness of cognitive auditory event-related p300 subcomponents in patients with Alzheimers disease? J Clin Neurophysiol 25:147-152
62. Kadir A, Darreh-Shori T, Almkvist O, Wall A, Langstrom B, Nordberg A (2007) Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET. Psychopharmacology 191:1005-1014
63. Karoumi B, Laurent A, Rosenfeld F, Rochet T, Brunon AM, Dalery J, d'Amato T, Saoud M (2000) Alteration of event related potentials in siblings discordant for schizophrenia. Schizophr Res 41:325-334
64. Katayama S, Ishizaki F, Yamamura Y, Khoriyama T, Kito S (1990) Effects of anticholinergic antiparkinsonian drugs on binding of muscarinic receptor subtypes in rat brain. Res Commun Chem Path 69:261-270
65. Kisley MA, Olincy A, Robbins E, Polk SD, Adler LE, Waldo MC, Freedman R (2003) Sensory gating impairment associated with schizophrenia persists into REM sleep. Psychophysiology 40:29-38
66. Kisley MA, Noecker TL, Guinther PM (2004) Comparison of sensory gating to mismatch negativity and self-reported perceptual phenomena in healthy adults. Psychophysiology 41:604-612
67. Kisley MA, Davalos DB, Engleman LL, Guinther PM, Davis HP (2005) Age-related change in neural processing of time-dependent stimulus features. Cogn Brain Res 25:913-925
68. Knight RT (1987) Aging decreases auditory event-related potentials to unexpected stimuli in humans. Neurobiol Aging 8:109-113
69. Laurent A, Garcia-Larrea L, d'Amato T, Bosson JL, Saoud M, Marie-Cardine M, Maugiere F, Dalery J (1999) Auditory event-related potentials and clinical scores in unmedicated schizophrenic patients. Psychiatry Res 86:229-238
70. Lee BJ, Lee JG, Kim YH (2007) A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia. J Psychopharmacol 21:421-427
71. Lefevre G, Sedek G, Jhee SS, Leibowitz MT, Huang HL, Enz A, Maton S, Ereshefsky L, Pommier F, Schmidli H, Appel-Dingemanse S (2008) Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. Clin Pharmacol Ther 83:106-114
72. Leiser SC, Dunlop J, Bowlby MR, Devilbiss DM (2011) Aligning strategies for using EEG as a surrogate biomarker: a review of preclinical and clinical research. Biochem Pharmacol 81:1408-1421
73. Light GA, Braff DL (2005) Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch Gen Psychiatry 62:127-136
74. Lijffijt M, Lane SD, Meier SL, Boutros NN, Burroughs S, Steinberg JL, Moeller FG, Swann AC (2009) P50, N100 and P200 sensory gating: relationships with behavioral inhibition, attention, and working memory. Psychophysiology 46:1059-1068
75. McGhie A, Chapman J (1961) Disorders of attention and perception in early schizophrenia. Br J Med Psychol 34:103-116
76. McNair DM, Lorr M, Droppleman LF (1971) Manual for the profile of mood states. Educational and Industrial Testing Service, Educational and Industrial Testing Service
77. Meador KJ, Loring DW, Adams RJ, Patel BR, Davis HC, Hammond EJ (1987) Central cholinergic systems and the P3 evoked potential. Int J Neurosci 33:199-205
78. Meador KJ, Loring DW, Lee GP, Taylor HS, Hughes DR, Feldman DS (1988) In vivo probe of central cholinergic systems. J Gerontol 43:M158-M162
79. Meador KJ, Loring DW, Davis HC, Sethi KD, Patel BR, Adams RJ, Hammond EJ (1989) Cholinergic and serotonergic effects on the P3 potential and recent memory. J Clin Exp Neuropsychol 11:252-260
80. Meador KJ, Loring DW, Hendrix N, Nichols ME, Oberzan R, Moore EE (1995) Synergistic anticholinergic and antiserotonergic effects in humans. J Clin Exp Neuropsychol 17:611-621
81. Mintzer J, Burns A (2000) Anticholinergic side-effects of drugs in elderly people. J R Soc Med 93:457-462
82. Miranda MI, Ramirez-Lugo L, Bermudez-Rattoni F (2000) Cortical cholinergic activity is related to the novelty of the stimulus. Brain Res 882:230-235
83. Näätänen R, Pakarinen S, Rinne T, Takegata R (2004) The mismatch negativity (MMN): towards the optimal paradigm. Clin Neurophysiol 115:140-144
84. Nagamoto HT, Adler LE, Waldo MC, Freedman R (1989) Sensory gating in schizophrenics and normal controls: effects of changing stimulation interval. Biol Psychiatry 25:549-561
85. Ogino S, Miyamoto S, Tenjin T, Kitajima R, Ojima K, Miyake N, Funamoto Y, Arai J, Tsukahara S, Ito Y, Tadokoro M, Anai K, Tatsunami S, Kubota H, Kaneda Y, Yamaguchi S (2011) Effects of discontinuation of long-term biperiden use on cognitive function and quality of life in schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 35:78-83
86. Olincy A, Braff DL, Adler LE, Cadenhead KS, Calkins ME, Dobie DJ, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Wagner BD, Freedman R (2010) Inhibition of the P50 cerebral evoked response to repeated auditory stimuli: results from the Consortium on Genetics of Schizophrenia. Schizophr Res 119:175-182
87. Onofrj M, Thomas A, Iacono D, Luciano AL, Di Iorio A (2003) The effects of a cholinesterase inhibitor are prominent in patients with fluctuating cognition: a part 3 study of the main mechanism of cholinesterase inhibitors in dementia. Clin Neuropharmacol 26:239-251
88. Oranje B, Geyer MA, Bocker KBE, Kenemans JL, Verbaten MN (2006) Prepulse inhibition and P50 suppression: commonalities and dissociations. Psychiatry Res 143:147-158
89. Patterson JV, Jin Y, Gierczak M, Hetrick WP, Potkin S, Bunney WE Jr, Sandman CA (2000) Effects of temporal variability on P50 and the gating ratio in schizophrenia: a frequency domain adaptive filter single-trial analysis. Arch Gen Psychiatry 57:57-64
90. Pekkonen E, Jousmaki V, Partanen J, Karhu J (1993) Mismatch negativity area and age-related auditory memory. Electroencephalogr Clin Neurophysiol 87:321-325
91. Pekkonen E, Jousmaki V, Kononen M, Reinikainen K, Partanen J (1994) Auditory sensory memory impairment in Alzheimer's disease: an event-related potential study. NeuroReport 5:2537-2540
92. Pekkonen E, Hirvonen J, Jaaskelainen IP, Kaakkola S, Huttunen J (2001) Auditory sensory memory and the cholinergic system: implications for Alzheimer's disease. NeuroImage 14:376-382
93. Pekkonen E, Jaaskelainen IP, Kaakkola S, Ahveninen J (2005) Cholinergic modulation of preattentive auditory processing in aging. NeuroImage 27:387-392
94. Pontifex MB, Hillman CH, Polich J (2009) Age, physical fitness, and attention: P3a and P3b. Psychophysiology 46:379-387
95. Potter DD, Pickles CD, Roberts RC, Rugg MD (2000) The effect of cholinergic receptor blockade by scopolamine on memory performance and the auditory P3. J Psychophysiol 14:11-23
96. Price GW, Michie PT, Johnston J, Innes-Brown H, Kent A, Clissa P et al (2006) A multivariate electrophysiological endophenotype, from a unitary cohort, shows greater research utility than any single feature in the Western Australian family study of schizophrenia. Biol Psychiatry 60:1-10
97. Pritchard W, Sokhadze E, Houlihan M (2004) Effects of nicotine and smoking on event-related potentials: a review. Nicotine Tob Res 6:961-984
98. Riekkinen P Jr, Paakkonen A, Karhu J, Partanen J, Soininen H, Laakso M, Riekkine P Sr (1997) THA disrupts mismatch negativity in Alzheimer disease. Psychopharmacology 133:203-206
99. Rinne T, Alho K, Ilmoniemi RJ, Virtanen J, Naatanen R (2000) Separate time behaviors of the temporal and frontal mismatch negativity sources. NeuroImage 12:14-19
100. Risch SC, Horner MD, McGurk SR, Palecko S, Markowitz JS, Nahas Z, DeVane CL (2007) Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study. Schizophr Res 93:131-135
101. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M (1999) Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 318:633-638
102. Sarter M, Lustig C, Taylor SF (2012) Cholinergic contributions to the cognitive symptoms of schizophrenia and the viability of cholinergic treatments. Neuropharmacology 62:1544-1553
103. Schiff S, Valenti P, Andrea P, Lot M, Bisiacchi P, Gatta A, Amodio P (2008) The effect of aging on auditory components of event-related brain potentials. Clin Neurophysiol 119:1795-1802
104. Schubert MH, Young KA, Hicks PB (2006) Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol Psychiatry 60:530-533
105. Semlitsch HV, Anderer P, Schuster P, Presslich O (1986) A solution for reliable and valid reduction of ocular artifacts, applied to the P300 ERP. Psychophysiology 23:695-703
106. Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dubé S, Mallinckrodt C, Bymaster FP, McKinzie DL, Felder CC (2008) Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 165:1033-1039
107. Simons CJP, Sambeth A, Krabbendam L, Pfeifer S, Van Os J, Riedel WJ (2011) Auditory P300 and N100 components as intermediate phenotypes for psychotic disorder: familial liability and reliability. Clin Neurophysiol 122:1984-1990
108. Souza VB, Muir WJ, Walker MT, Glabus MF, Roxborough HM, Sharp CW, Dunan JR, Blackwood DH (1995) Auditory P300 event-related potentials and neuropsychological performance in schizophrenia and bipolar affective disorder. Biol Psychiatry 37:300-310
109. Tandon R, Mann NA, Eisner WH, Coppard N (1990) Effect of anticholinergic medication on positive and negative symptoms in medication-free schizophrenic patients. Psychiatry Res 31:235-241
110. Tandon R, DeQuardo JR, Goodson J, Mann NA, Greden JF (1992) Effect of anticholinergics on positive and negative symptoms in schizophrenia. Psychopharmacol Bull 28:297-302
111. Thomas C, vom Berg I, Rupp A, Seidl U, Schroder J, Roesch-Ely D, Kreisel SH, Mundt C, Weisbrod M (2010) P50 gating deficit in Alzheimer dementia correlates to frontal neuropsychological function. Neurobiol Aging 31:416-424
112. Turetsky BI, Cannon TD, Gur RE (2000) P300 subcomponent abnormalities in schizophrenia: III. Deficits in unaffected siblings of schizophrenic probands. Biol Psychiatry 47:380-390
113. Turetsky BI, Bilker WB, Siegel SJ, Kohler CG, Gur RE (2009) Profile of auditory information-processing deficits in schizophrenia. Psychiatry Res 165:27-37
114. Umbricht D, Krljes S (2005) Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res 76:1-23
115. van der Stelt O, Lieberman JA, Belger A (2005) Auditory P300 in high-risk, recent-onset and chronic schizophrenia. Schizophr Res 77:309-320
116. Wezenberg E, Verkes RJ, Sabbe BG, Ruigt GS, Hulstijn W (2005) Modulation of memory and visuospatial processes by biperiden and rivastigmine in elderly healthy subjects. Psychopharmacology 181:582-594
117. Williams TJ, Nuechterlein KH, Subotnik KL, Yee CM (2011) Distinct neural generators of sensory gating in schizophrenia. Psychophysiology 48:470-478
118. Zouridakis G, Boutros NN (1992) Stimulus parameter effects on the P50 evoked response. Biol Psychiatry 32:839-841